A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved ... The data with the CRISPR/Cas9 drug CTX001 is still very early-stage, coming from just seven thalassaemia ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can ... to begin an early stage trial of CTX001, a gene therapy derived from ...

CRISPR Therapeutics' stock is down 19% since December ... but $35M in collaboration revenue from Vertex and a net loss of $37.311M. Despite pioneering technology, CRISPR faces slow gene therapy ...